Rpo LLC Acquires New Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Rpo LLC acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,787 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cibc World Markets Corp bought a new position in shares of Allogene Therapeutics in the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS purchased a new stake in Allogene Therapeutics in the 4th quarter valued at about $43,000. MML Investors Services LLC bought a new position in Allogene Therapeutics in the 3rd quarter worth about $56,000. EP Wealth Advisors LLC increased its position in shares of Allogene Therapeutics by 125.6% during the third quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after acquiring an additional 13,625 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of Allogene Therapeutics during the third quarter valued at approximately $91,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Friday, March 14th. HC Wainwright lowered their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 19th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Trading Up 5.1 %

Shares of NASDAQ:ALLO opened at $1.44 on Thursday. The company has a market capitalization of $312.86 million, a PE ratio of -0.92 and a beta of 1.02. Allogene Therapeutics, Inc. has a 12-month low of $1.30 and a 12-month high of $4.30. The business has a 50 day moving average of $1.83 and a two-hundred day moving average of $2.22.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. Equities research analysts predict that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This trade represents a 0.88 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 104,866 shares of company stock worth $194,461. 24.30% of the stock is owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).